GSK files for new Synflorix use in EU; Australian activists lobby for doc-payment disclosure;

 @FiercePharma: Sunshine in Australia? Critics call for disclosure of pharma payments to individual docs. Report | Follow @FiercePharma

> GlaxoSmithKline ($GSK) asked European regulators to approve a new use for its pneumococcal vaccine, Synflorix, to prevent pneumonia in infants and small children. Report

> Australian public health advocates are lobbying for drugmakers to disclose payments to individual doctors, rather than report payment totals as rules now require. Report

> Bayer's supervisory board officially elected former CEO Werner Wenning as chairman, after a shareholder's election in April. Report

> Japan's Mitsui plans to snap up another 25% stake in the pharmaceutical ingredient maker Arch Pharmalabs, increasing its overall position in the Indian company to 30%. Report

> Reckitt Benckiser tapped Smith & Nephew's Adrian Hennah as its new chief financial officer, counting on Hennah's healthcare experience to help it expand its health brands. Report

> UCB inaugurated its new 65 million euro biotech plant in Belgium, where it plans to turn out antibody-based therapies for clinical studies and develop full-scale manufacturing processes. Report

Medical Device News

 @FierceMedDev: Life Technologies and Bristol-Myers Squibb are partnering to develop companion Dx. Who's next? Release | Follow @FierceMedDev

 @MarkHFierce: With all the problems metal hip implants are causing, some good news: at least they don't appear to trigger cancer. Report | Follow @MarkHFierce

 @DamianFierce: Danaher Corp. is spending $338M to pick up Dx company Iris International. News | Follow @DamianFierce

> Life Technologies reels in Bristol-Myers Squibb as companion Dx partner. Article

> Trouble thinking? There may be a brain implant for that. Item

Biotech News

 @FierceBiotech: Little NovaDigm races Pfizer, Glaxo in race to develop MRSA vaccines. Item | Follow @FierceBiotech

 @JohnCFierce: Targacept sharpens well-used budget ax after another drug flames out. More | Follow @JohnCFierce

 @RyanMFierce: Wow. China's BGI buying rival DNA sequencing outfit Complete Genomics for $3.15 per share (value $117.6M). Release | Follow @RyanMFierce

> Sanofi workers plan protests as execs prep for big job cuts next week. Article

> Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness. Story

> Threshold shares slammed after lead cancer drug trips on survival goal. News

CRO News

> Pfizer launches joint venture with Chinese API maker. Story

> Patheon lifts profit outlook after strong quarter. News

> INC expands clinical ops in South Korea. Article

> Quintiles signs on to sell Sinclair IS drugs in Mexico. More

Biotech IT News

> Boehringer Ingelheim debuts pharma game 'Syrum' on Facebook. Article

> Pfizer taps cloud computing to gain control of supply chain. Story

> Illumina partners with Partners HealthCare to combine sequencing and software. Report

And Finally ... Cost-cutting in China is spawning violent attacks against hospital doctors and other healthcare workers. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.